Janus Henderson Group PLC Raises Stock Holdings in Aurinia Pharmaceuticals Inc $AUPH

Janus Henderson Group PLC raised its holdings in shares of Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) (TSE:AUP) by 9.7% in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 757,435 shares of the biotechnology company’s stock after purchasing an additional 66,806 shares during the quarter. Janus Henderson Group PLC owned 0.59% of Aurinia Pharmaceuticals worth $11,225,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Centaurus Financial Inc. acquired a new position in shares of Aurinia Pharmaceuticals in the 1st quarter valued at approximately $904,000. Quantinno Capital Management LP grew its position in shares of Aurinia Pharmaceuticals by 6.4% during the first quarter. Quantinno Capital Management LP now owns 87,614 shares of the biotechnology company’s stock worth $1,298,000 after buying an additional 5,285 shares in the last quarter. OMERS ADMINISTRATION Corp acquired a new stake in shares of Aurinia Pharmaceuticals during the first quarter worth approximately $1,340,000. Healthcare of Ontario Pension Plan Trust Fund bought a new stake in shares of Aurinia Pharmaceuticals in the first quarter worth $4,080,000. Finally, Renaissance Technologies LLC increased its stake in shares of Aurinia Pharmaceuticals by 4.6% in the first quarter. Renaissance Technologies LLC now owns 1,663,835 shares of the biotechnology company’s stock worth $24,658,000 after buying an additional 73,700 shares during the last quarter. 36.83% of the stock is currently owned by hedge funds and other institutional investors.

Aurinia Pharmaceuticals Price Performance

AUPH opened at $14.93 on Wednesday. The firm has a market cap of $1.92 billion, a price-to-earnings ratio of 6.88 and a beta of 1.42. Aurinia Pharmaceuticals Inc has a fifty-two week low of $10.34 and a fifty-two week high of $19.25. The company’s 50-day moving average price is $15.93 and its 200 day moving average price is $15.34. The company has a quick ratio of 5.01, a current ratio of 5.55 and a debt-to-equity ratio of 0.08.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last issued its earnings results on Thursday, May 7th. The biotechnology company reported $0.25 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.18 by $0.07. The firm had revenue of $77.71 million for the quarter, compared to analysts’ expectations of $76.98 million. Aurinia Pharmaceuticals had a net margin of 99.97% and a return on equity of 26.62%. As a group, sell-side analysts expect that Aurinia Pharmaceuticals Inc will post 0.81 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on the stock. Weiss Ratings downgraded shares of Aurinia Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Friday, May 15th. Zacks Research downgraded shares of Aurinia Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, July 21st. One analyst has rated the stock with a Buy rating and five have assigned a Hold rating to the company. According to data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $17.33.

Insider Buying and Selling at Aurinia Pharmaceuticals

In related news, CEO Kevin Tang purchased 206,005 shares of the business’s stock in a transaction that occurred on Tuesday, June 2nd. The shares were acquired at an average price of $15.28 per share, with a total value of $3,147,756.40. Following the acquisition, the chief executive officer owned 13,044,106 shares in the company, valued at approximately $199,313,939.68. This trade represents a 1.60% increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In the last 90 days, insiders purchased 814,606 shares of company stock worth $12,455,129. 10.40% of the stock is currently owned by corporate insiders.

Aurinia Pharmaceuticals Profile

Aurinia Pharmaceuticals Inc is a clinical?stage biopharmaceutical company focused on developing and commercializing therapies for autoimmune diseases. The company’s proprietary molecule, voclosporin, is designed to selectively inhibit calcineurin and reduce inflammation associated with autoimmune responses. Aurinia operates research and development facilities in Canada and the United States, leveraging collaborations with academic institutions and contract research organizations to advance its clinical pipeline.

The company’s lead product, voclosporin (marketed as LUPKYNIS), received approval from the U.S.